JournalQ1· SCImago 2025
NEJM Evidence
ISSN 2766-5526
- Q1Quartile
- 3.00SJR
- 19h-index
- 3papers summarised
About this journal
NEJM Evidence is a Q1 journal by SCImago Journal Rank (2025 data), with an SJR of 3.00 and an h-index of 19. Pofolia holds AI summaries of 3 paper(s) from this journal; the most cited is “Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma” (1457 citations).
The quartile (Q1–Q4) is the journal's percentile position within its subject area by SCImago Journal Rank; Q1 is the top 25%. What is a Q1 journal?
Papers we summarise from this journal
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma2022 · 1457 citations
- Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease2026 · 1 citations
- Cyclosporiasis Outbreak in Michigan, May–July 2026 — An Interim Report2026 · 0 citations
Journals in the same field
| Journal | Quartile | SJR | Summaries |
|---|---|---|---|
| Morbidity and Mortality Weekly Report | Q1 | 8.00 | 1 |
| Journal of Microbiology, Immunology and Infection | Q1 | 1.00 | 1 |
| American Journal of Tropical Medicine and Hygiene | Q2 | 1 | |
| Zoonoses (Ireland) | Q2 | 1 |
Follow these journals on Pofolia
Pick your fields and new papers from their journals land in your feed every day with AI summaries. Free.
Start free